Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study
Ibrahim Ayada, Laurens A. van Kleef, Huai Zhang, et al.
EBioMedicine (2022) Vol. 87, pp. 104392-104392
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 281
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 54
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 30
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease
Xiaodong Zhou, Seung Up Kim, Terry Cheuk‐Fung Yip, et al.
Gut (2024) Vol. 73, Iss. 11, pp. 1883-1892
Closed Access | Times Cited: 17
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu, et al.
Hepatology International (2025)
Closed Access | Times Cited: 3
Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
J Bernhard, L Galli, Walter S. Speidl, et al.
Current Cardiology Reports (2025) Vol. 27, Iss. 1
Open Access | Times Cited: 2
Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
Anders Mellemkjær, Mikkel Breinholt Kjær, David Haldrup, et al.
European Journal of Internal Medicine (2023) Vol. 122, pp. 28-34
Open Access | Times Cited: 35
MAFLD as part of systemic metabolic dysregulation
Jing Zhao, Lu Liu, Yingying Cao, et al.
Hepatology International (2024) Vol. 18, Iss. S2, pp. 834-847
Closed Access | Times Cited: 14
Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)
Jian‐Gao Fan, Xiaoyuan Xu, Rui-Xu Yang, et al.
Journal of Clinical and Translational Hepatology (2024) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 13
Pravastatin reduces all-cause mortality in elderly at risk of liver fibrosis: post-hoc analysis of the PROSPER trial
Vivian de Jong, Willy Theel, Manuel Castro Cabezas, et al.
JHEP Reports (2025), pp. 101337-101337
Open Access | Times Cited: 1
From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention
Benedetta Maria Motta, Mario Masarone, Pietro Torre, et al.
Cancers (2023) Vol. 15, Iss. 22, pp. 5458-5458
Open Access | Times Cited: 17
Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data
Hisayuki Katsuyama, Mariko Hakoshima, Emika Kaji, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1001-1001
Open Access | Times Cited: 6
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting
Alina M. Allen, Michael Charlton, Kenneth Cusi, et al.
Postgraduate Medicine (2024) Vol. 136, Iss. 3, pp. 229-245
Open Access | Times Cited: 5
Potential Mechanisms for Shenling Baizhu Powder in the Treatment of MAFLD Based on Network Pharmacology and Experimental Validation
Anni Zheng, Sufei Song, Qiuling Xu, et al.
Natural Product Communications (2025) Vol. 20, Iss. 1
Open Access
Predicting Metabolic Dysfunction Associated Steatotic Liver Disease Risk Using Patient-Derived Induced Pluripotent Stem Cells
Yuanyuan Qin, Parth D. Chhetri, Elizabeth Theusch, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy?
Konstantinos Arvanitakis, Theocharis Koufakis, Εvangelos Cholongitas, et al.
Pharmacology & Therapeutics (2025), pp. 108811-108811
Open Access
Andrographolide Inhibits the NF-κB Signaling Pathway and Alleviates High-Fat Diet-Induced Hepatic Inflammation in a Mouse Model of Nonalcoholic Fatty Liver Disease
Weiwen Hu, Yilin Chen, Wenhong Tan, et al.
Natural Product Communications (2025) Vol. 20, Iss. 2
Open Access
Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment
Marios Zisis, Maria Chondrogianni, Θεόδωρος Ανδρουτσάκος, et al.
Biomolecules (2025) Vol. 15, Iss. 3, pp. 324-324
Open Access
Association between the NHHR and hepatic steatosis and liver fibrosis: a population-based study
Xiao-Xian Yang, Yan Han, Rui Guo, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Resmetirom directly inhibits lipid accumulation in human liver-derived organoids
Jiajing Li, Ibrahim Ayada, Qiuwei Pan
Journal of Hepatology (2025)
Closed Access
Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction
Kuo Du, David S. Umbaugh, Liuyang Wang, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Anti-fibrotic effects of statin drugs: A review of evidence and mechanisms
David Dolivo, Charlotte R. Reed, Kristine A. Gargiulo, et al.
Biochemical Pharmacology (2023) Vol. 214, pp. 115644-115644
Closed Access | Times Cited: 11
Protective effects of statins on the incidence of NAFLD–related decompensated cirrhosis in T2DM
Szu‐Yuan Wu, Wan‐Ming Chen, Ming‐Feng Chiang, et al.
Liver International (2023) Vol. 43, Iss. 10, pp. 2232-2244
Closed Access | Times Cited: 11
Autophagy and hepatic lipid metabolism: mechanistic insight and therapeutic potential for MASLD
Sana Raza, Sangam Rajak, Paul M. Yen, et al.
npj Metabolic Health and Disease (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 4
Statins and non-alcoholic fatty liver disease: A concise review
Evelyn Nunes Goulart da Silva Pereira, Ricardo Franco, Raul D. Santos, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117805-117805
Open Access
Page 1 - Next Page

Scroll to top